150 related articles for article (PubMed ID: 23704979)
1. EGFR, FLT1 and heparanase as markers identifying patients at risk of short survival in cholangiocarcinoma.
Hoffmann AC; Goekkurt E; Danenberg PV; Lehmann S; Ehninger G; Aust DE; Stoehlmacher-Williams J
PLoS One; 2013; 8(5):e64186. PubMed ID: 23704979
[TBL] [Abstract][Full Text] [Related]
2. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors.
Andersen JB; Spee B; Blechacz BR; Avital I; Komuta M; Barbour A; Conner EA; Gillen MC; Roskams T; Roberts LR; Factor VM; Thorgeirsson SS
Gastroenterology; 2012 Apr; 142(4):1021-1031.e15. PubMed ID: 22178589
[TBL] [Abstract][Full Text] [Related]
3. Trefoil factors: tumor progression markers and mitogens via EGFR/MAPK activation in cholangiocarcinoma.
Kosriwong K; Menheniott TR; Giraud AS; Jearanaikoon P; Sripa B; Limpaiboon T
World J Gastroenterol; 2011 Mar; 17(12):1631-41. PubMed ID: 21472131
[TBL] [Abstract][Full Text] [Related]
4. High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma.
Xu YF; Ge FJ; Han B; Yang XQ; Su H; Zhao AC; Zhao MH; Yang YB; Yang J
World J Gastroenterol; 2015 Mar; 21(11):3256-65. PubMed ID: 25805932
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of NQO1 expression in intrahepatic cholangiocarcinoma.
Wakai T; Shirai Y; Sakata J; Matsuda Y; Korita PV; Takamura M; Ajioka Y; Hatakeyama K
Int J Clin Exp Pathol; 2011 Apr; 4(4):363-70. PubMed ID: 21577322
[TBL] [Abstract][Full Text] [Related]
6. A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma.
Zou W; Wang Z; Wang F; Li L; Liu R; Hu M
BMC Cancer; 2021 May; 21(1):608. PubMed ID: 34034689
[TBL] [Abstract][Full Text] [Related]
7. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.
Xu L; Hausmann M; Dietmaier W; Kellermeier S; Pesch T; Stieber-Gunckel M; Lippert E; Klebl F; Rogler G
BMC Cancer; 2010 Jun; 10():302. PubMed ID: 20565817
[TBL] [Abstract][Full Text] [Related]
8. High expression of matrix metalloproteinase-9 indicates poor prognosis in human hilar cholangiocarcinoma.
Sun Q; Zhao C; Xia L; He Z; Lu Z; Liu C; Jia M; Wang J; Niu J
Int J Clin Exp Pathol; 2014; 7(9):6157-64. PubMed ID: 25337264
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.
Yoshikawa D; Ojima H; Iwasaki M; Hiraoka N; Kosuge T; Kasai S; Hirohashi S; Shibata T
Br J Cancer; 2008 Jan; 98(2):418-25. PubMed ID: 18087285
[TBL] [Abstract][Full Text] [Related]
10. Microsomal prostaglandin E synthase-1 inhibits PTEN and promotes experimental cholangiocarcinogenesis and tumor progression.
Lu D; Han C; Wu T
Gastroenterology; 2011 Jun; 140(7):2084-94. PubMed ID: 21354147
[TBL] [Abstract][Full Text] [Related]
11. Role of thymidylate synthase and dihydropyrimidine dehydrogenase mRNA in intrahepatic cholangiocarcinoma.
Morine Y; Shimada M; Utsunomiya T; Imura S; Ikemoto T; Hanaka J; Kanamoto M; Kurita N; Miyake H
Surg Today; 2012 Jan; 42(2):135-40. PubMed ID: 22143355
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma.
Shen DY; Zhan YH; Wang QM; Rui G; Zhang ZM
Liver Int; 2013 Jan; 33(1):137-48. PubMed ID: 23121546
[TBL] [Abstract][Full Text] [Related]
13. SOX4 is associated with poor prognosis in cholangiocarcinoma.
Wang W; Zhang J; Zhan X; Lin T; Yang M; Hu J; Han B; Hu S
Biochem Biophys Res Commun; 2014 Sep; 452(3):614-21. PubMed ID: 25181339
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of C-met Expression in Cholangiocarcinoma.
Mao ZY; Zhu GQ; Ren L; Guo XC; Su D; Bai L
Technol Cancer Res Treat; 2016 Apr; 15(2):227-33. PubMed ID: 25873560
[TBL] [Abstract][Full Text] [Related]
15. Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients.
Gao Q; Zhao YJ; Wang XY; Guo WJ; Gao S; Wei L; Shi JY; Shi GM; Wang ZC; Zhang YN; Shi YH; Ding J; Ding ZB; Ke AW; Dai Z; Wu FZ; Wang H; Qiu ZP; Chen ZA; Zhang ZF; Qiu SJ; Zhou J; He XH; Fan J
Gastroenterology; 2014 May; 146(5):1397-407. PubMed ID: 24503127
[TBL] [Abstract][Full Text] [Related]
16. EYA4 gene functions as a prognostic marker and inhibits the growth of intrahepatic cholangiocarcinoma.
Hao XY; Cai JP; Liu X; Chen W; Hou X; Chen D; Lai JM; Liang LJ; Yin XY
Chin J Cancer; 2016 Jul; 35(1):70. PubMed ID: 27469137
[TBL] [Abstract][Full Text] [Related]
17. Platelet-derived growth factor may be a potential diagnostic and prognostic marker for cholangiocarcinoma.
Boonjaraspinyo S; Boonmars T; Wu Z; Loilome W; Sithithaworn P; Nagano I; Pinlaor S; Yongvanit P; Nielsen PS; Pairojkul C; Khuntikeo N
Tumour Biol; 2012 Oct; 33(5):1785-802. PubMed ID: 22733151
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma.
Maeda T; Taguchi K; Aishima S; Shimada M; Hintz D; Larusso N; Gores G; Tsuneyoshi M; Sugimachi K; Wands JR; de la Monte SM
Cancer Detect Prev; 2004; 28(5):313-8. PubMed ID: 15542253
[TBL] [Abstract][Full Text] [Related]
19. Characterization of EGFR family gene aberrations in cholangiocarcinoma.
Yang X; Wang W; Wang C; Wang L; Yang M; Qi M; Su H; Sun X; Liu Z; Zhang J; Qin X; Han B
Oncol Rep; 2014 Aug; 32(2):700-8. PubMed ID: 24927194
[TBL] [Abstract][Full Text] [Related]
20. A novel prognostic biomarker for cholangiocarcinoma: circRNA Cdr1as.
Jiang XM; Li ZL; Li JL; Xu Y; Leng KM; Cui YF; Sun DJ
Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):365-371. PubMed ID: 29424892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
